Clinical Trials Directory

Trials / Unknown

UnknownNCT04493515

Oral Oxytocin's Effects on Attention Control

Oral Oxytocin's Effects on Attention Control: An Eye-tracking Study

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
University of Electronic Science and Technology of China · Academic / Other
Sex
Male
Age
18 Years – 30 Years
Healthy volunteers
Accepted

Summary

The main aim of the study is to investigate whether orally administered oxytocin (24IU) could modulate attention control using a social-emotional saccade/antisaccade eye-tracking paradigm.

Detailed description

Numerous studies have reported the effect of intranasally administered oxytocin on attentional processing including stimulus-driven bottom-up processing and top-down goal-directed inhibitory control. However, it is unclear whether the functional effects are mediated by the peptide directly entering the brain or indirectly via raising peripheral concentrations. One possible method of producing a similar pattern of increased peripheral oxytocin concentrations but without the possibility of direct entry into the brain would be to administer the peptide lingually. In the present double-blind, between-subject, placebo-controlled study, 80 healthy male subjects will be recruited and receive either oxytocin (24IU) or placebo control administered orally (lingual). 45 minutes after treatment subjects are required to complete a social-emotional saccade/antisaccade eye-tracking paradigm. This paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of orally administered oxytocin.

Conditions

Interventions

TypeNameDescription
DRUGOral OxytocinAdministration of oxytocin orally (24 IU)
DRUGOral PlaceboAdministration of placebo orally (24 IU)

Timeline

Start date
2020-07-28
Primary completion
2020-12-31
Completion
2021-12-31
First posted
2020-07-30
Last updated
2020-07-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04493515. Inclusion in this directory is not an endorsement.